ADAMAS PHARMACEUTICALS
Adamas Pharmaceuticals, Inc. engages in the development and commercialization of controlled release combination therapeutics to treat healthcare problems, primarily in the areas of infectious diseases and central nervous system disorders. It also develops novel extended release and combination products for symptomatic treatment of dementia. The company was incorporated in 2000 and is headquartered in Emeryville, California with operations in India, the United States, and Singapore.
ADAMAS PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2000-01-01
Address:
Emeryville, California, United States
Country:
United States
Website Url:
http://www.adamaspharma.com
Total Employee:
51+
Status:
Active
Contact:
5104280519
Email Addresses:
[email protected]
Total Funding:
483.2 M USD
Technology used in webpage:
Domain Not Resolving IPv6 ReCAPTCHA Cloudflare Hosting JsDelivr Cloudflare JS CDN JS Cloudflare CDN Gravity Forms Ruby On Rails Token
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
ANI Pharmaceuticals
ANI Pharmaceuticals manufactures oral solid dose products, as well as liquids and topicals.
BioVectra
BioVectra offers contract development and manufacturing capacity for intermediates and active pharmaceutical ingredients.
Windtree Therapeutics
Windtree is a clinical-stage focused on developing novel surfactant therapies for respiratory diseases and other potential applications.
MISSION Therapeutics
MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).
Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Annovis Bio
Annovis Bio develops novel treatments for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.
Sanofi
Sanofi is engaged in the research, development, manufacturing, and marketing of innovative therapeutic solutions.
Stoke Therapeutics
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
Tonix Pharmaceuticals
Tonix Pharmaceuticals develops pharmaceutical products for central nervous system disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 1996-07-30 | Future Domain | Future Domain acquired by Adamas Pharmaceuticals | N/A |
Investors List
Northgate Capital
Northgate Capital investment in Series D - Adamas Pharmaceuticals
DAG Ventures
DAG Ventures investment in Series D - Adamas Pharmaceuticals
Aeris Capital
Aeris Capital investment in Series D - Adamas Pharmaceuticals
Mohr Davidow Ventures
Mohr Davidow Ventures investment in Series D - Adamas Pharmaceuticals
Mohr Davidow Ventures
Mohr Davidow Ventures investment in Series B - Adamas Pharmaceuticals
Official Site Inspections
http://www.adamaspharma.com
- Host name: ec2-3-214-152-230.compute-1.amazonaws.com
- IP address: 3.214.152.230
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Adamas Pharmaceuticals"
Adamas Pharmaceuticals - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 5104280519 Adamas Pharmaceuticals, Inc. engages in the development and commercialization of controlled release combination …See details»
Adamas Pharmaceuticals, Inc. | LinkedIn
Adamas Pharmaceuticals, Inc. Pharmaceutical Manufacturing Emeryville, California 18,309 followers Making everyday life significantly better for people affected by neurological diseases.See details»
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals ...
Oct 11, 2021 Investors may also obtain, at no charge, the documents filed with or furnished to the SEC by (i) Supernus under the “Investor Relations” section of Supernus’s website at …See details»
Adamas Pharmaceuticals Inc (Form: SC14D9C, Received: …
On October 10, 2021, Adamas Pharmaceuticals, Inc., a Delaware corporation (“Adamas” or the “Company”) entered into an Agreement and Plan of Merger, by and among Adamas, Supernus …See details»
Adamas Pharmaceuticals - Craft
Adamas Pharmaceuticals discovers and develops therapies to improve the daily lives of people affected by chronic neurologic disorders. The Company pioneered a platform to develop …See details»
Adamas Appoints Anna Richo to Board of Directors - Yahoo Finance
Sep 1, 2020 “We are delighted to welcome Anna to our board during this exciting time of growth for us as a commercial organization,” said David L. Mahoney, Chairman, Adamas. ... 510-450 …See details»
Adamas Pharmaceuticals - Products, Competitors, Financials, …
About Adamas Pharmaceuticals. Adamas (NASDAQ: ADMS) is a pharmaceutical company focused on developing small molecule, advantaged therapeutics to treat neurological and …See details»
Adamas Pharmaceuticals, Inc. Company Information - Drugs.com
Jan 6, 2017 Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided …See details»
Adamas announces changes to its Board of Directors with the
Nov 23, 2020 He played a critical role through multiple successful NDA submissions and our evolution into a successful commercial organization. We wish him well,” said David L. …See details»
Adamas Pharma Appoints New Chief Financial Officer - BioSpace
Jun 28, 2017 Merriweather will be responsible for leading the company’s financial and administration organization including its established teams in finance, accounting, SEC …See details»
Adamas Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 23, 2021 Media: Sarah Mathieson Vice President, Corporate Communications 510-450-3528 [email protected]. Investors: Peter Vozzo Managing Director, …See details»
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals ...
Oct 11, 2021 ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Adamas Pharmaceuticals, Inc. …See details»
Adamas Completes Acquisition of OSMOLEX ER® - Nasdaq
Jan 5, 2021 Media: Sarah Mathieson Vice President, Corporate [email protected]. Investors: Peter Vozzo Managing Director, …See details»
Adamas to Present at Upcoming June Conferences - Business Wire
May 27, 2021 Media: Sarah Mathieson Vice President, Corporate Communications 510-450-3528 [email protected] Investors: Peter Vozzo Managing Director …See details»
Adamas Pharmaceuticals - CB Insights
Spyros is an experienced biopharmaceutical executive, recognized neuroscientist, neurodegenerative disease clinician and change agent. Prior to joining Vigil. he served as …See details»
Adamas Reports Second Quarter 2021 Financial Results
Aug 9, 2021 Media: Sarah Mathieson Vice President, Corporate Communications 510-450-3528 [email protected] Investors: Peter Vozzo Westwicke/ICR 443-213-0505 …See details»
Adamas Completes Acquisition of OSMOLEX ER® - GlobeNewswire
Jan 5, 2021 Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition...See details»
Adamas to Announce Second Quarter Financial Results and Host …
Aug 2, 2021 Media: Sarah Mathieson Vice President of Corporate Communications 510-450-3528 [email protected]. Investors: Peter Vozzo Managing Director, …See details»
Adamas Provides Preliminary Fourth Quarter and Full Year
Jan 13, 2021 -- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 ---- Product sales of GOCOVRI® expected to be $19.8 million for …See details»
Adamas Named 2021 Finalist in the New Therapeutics Category of …
Oct 1, 2021 Media: Sarah Mathieson Vice President of Corporate Communications 510-450-3528 [email protected] Investors: Peter Vozzo Westwicke 443-213-0505 …See details»